


**BOOK EARLY AND
SAVE €400**

11 – 13 June | Munich, Germany

www.targeted-radiopharma.com



TRP

**TARGETED
RADIOPHARMACEUTICALS
SUMMIT**

Overcoming the technical, logistical and translational challenges of delivering meaningful clinical efficacy with radionuclide therapies

Expert Speakers include:



Richard Baum
Theranostics Center
for Molecular
Radiotherapy and
Molecular Imaging
**Zentralklinik Bad
Berka**



Chris Leamon
Vice President of
Research
Endocyte



Marian Meckel
Research &
Development Lead
ITG



Cristina Müller
Research Group
Leader at Paul
Scherrer Institute
and Private Docent
ETH Zurich



Matt Harris
Chief Executive
Officer
**Clarity
Pharmaceuticals**



Daniel Stevens
Global Development
Lead
IPSEN

Welcome to the Targeted Radiopharmaceuticals Summit

This industry-led forum is designed to accelerate progress of theranostic and diagnostic radiopharmaceuticals. Developed with insight from the likes of **AAA, Endocyte, Bayer & Actinium Pharmaceuticals**, this program will share key learnings on the discovery, development and commercialisation of targeted radiopharmaceuticals.

Attend to learn, see how the industry pioneers are honing the radiochemistry to optimise the **preclinical effectiveness** of their candidates. See how others have navigated a path to the clinic and ensure you have maximised the chance of regulatory approval. You will also discover how they have prepared for the **logistical and commercial challenges** of producing robust drug products.

Our expert speakers will provide you with insight that will enable you to stay ahead in this increasingly competitive space, and achieve meaningful clinical results.

Explore more than just the talks and immerse yourself in our interactive content; places are available for the 3 hour technical workshop and on the site visit to a local nuclear reactor. You will return to work with a refreshed perspective and new ideas that will help you drive your products to clinical success.

Hear what Hanson Wade's attendees have said about our meetings

“Overall great conference with a combination of excellent speakers and focused, relevant content. A Good balance of technical and business driven talks”

Eisai

“I thought the conference was very focused. It was time well spent. I learned a lot and had productive networking sessions”


Genentech




Top 5 Reasons To Attend:



Hear our keynote speaker **Richard Baum** discuss how targeted imaging and therapeutic radionuclide therapies have, and will continue to, drive better results in cancer



Gain insight into various methods of targeting, including: small molecules with **Chris Leamon**, Nanotechnology with **Twan Lammers**, and biologics with **Tony Lahoutte**



Explore the potential of new and exotic radioisotopes for theranostics and imaging with **Cristina Müller**



Maximise the therapeutic application of your radio-immunotherapy using insight gained from **Dale Ludwig**



Overcome the key preclinical and dosimetry challenges to give greater confidence in the clinical results with **Jostein Dahle and Marc Robillard**

YOUR EXPERT SPEAKERS



Christiane Smerling
Head of Nuclear
Medicine & Imaging
3B Pharmaceuticals



Twan Lammers
Professor, Head of
Department
Aachen University



Dale Ludwig
Chief Scientific Officer
**Actinium
Pharmaceuticals**



Maurizio Mariani
Head of Research
**Advanced
Accelerator
Applications, A
Novartis Company**



Urs Hagemann
Laboratory Head
Bayer



Tony Lahoutte
Chief Scientific
Officer
Camel-IDS



Matt Harris
Chief Executive Officer
**Clarity
Pharmaceuticals**



Chris Leamon
Vice President of
Research
Endocyte



Cristina Müller
Research Group
Leader at Paul
Scherrer Institute and
Private Docent
ETH Zurich



Diane Chisholm
Head of Clinical
Operations
**Blue Earth
Diagnostics**



Daniel Stevens
Global Development
Lead
IPSEN



Marian Meckel
Research &
Development Lead
ITG



Jostein Dahle
Chief Scientific Officer
Nordic Nanovector



Amal Saidi
Scientist
OranoMed



Izabella Tworowska
Chief Scientific
Officer
Radiomedix



Marc Robillard
Chief Executive
Officer
**Tagworks
Pharmaceuticals**



Chris Behrenbruch
Chief Executive
Officer
**Telix
Pharmaceuticals**



Greg Mullen
Chief Executive
Officer
Theragnostics



Melpomeni Fani
Head of
Radiopharmaceutical
Chemistry Research
and Development
**University Hospital
Basel**



Richard Baum
Theranostics Center
for Molecular
Radiotherapy and
Molecular Imaging
**Zentralklinik Bad
Berka**

“ Good conference
with a lot of relevant
speakers ”

GSK, Past Hanson Wade Attendee

CONFERENCE DAY ONE

WEDNESDAY, 12 JUNE

	8.50 Chair's Opening Remarks
Richard Baum Theranostics Center for Molecular Radiotherapy and Molecular Imaging Zentralklinik Bad Berka	9.00 Keynote Presentation: The Power of Precision Oncology: Past, Present and Future of Molecular Imaging and Targeted Radioisotope Therapy of Cancer
Assessing the Therapeutic Potential of Novel Targets & Radioisotopes	
Christiane Smerling Head of Nuclear Medicine & Imaging 3B Pharmaceuticals	9.30 New Solid Tumor Targets for Targeted Radiopharmaceutical Therapy Using Peptides and Small Molecules <ul style="list-style-type: none"> • Differentiate between target classes • Understand the criteria targets are required to meet • Learn how to identify a good target for a certain class of targeting molecules • Discuss potential pitfalls of peptides and small molecules • Review 3BP's hit identification platform • Learn from successful examples of successful de novo hit generation
	10.00 Speed Networking & Morning Refreshments This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the radiopharmaceutical field and establish meaningful business relationships to pursue for the rest of the conference.
Cristina Müller Research Group Leader at Paul Scherrer Institute and Private Docent ETH Zurich	11.30 Exotic Radionuclides for Radiotheragnostic Applications <ul style="list-style-type: none"> • Presentation of the concept of radiotheragnostics using radioisotopes of the same element • Production and preclinical investigations of scandium and terbium radioisotopes • First-in-human application
Matt Harris Chief Executive Officer Clarity Pharmaceuticals	12.00 Copper-64/67 Targeted Radiopharmaceuticals, Next Generation Theranostics <ul style="list-style-type: none"> • Clarity is in Phase 2a targeted radiopharmaceutical therapy trial. • Discuss peptide receptor radiopharmaceutical therapies which utilise Copper-64 for PET imaging and Copper-67 for Beta emitting therapy • Copper-64 has advantages in dosimetry and centralised manufacture, while Copper-67 has a versatile half-life suited to peptides
	12.30 Lunch
	12.30 Optional Site Visit <ul style="list-style-type: none"> • Join us in a visit to the Munich Technical University's FRMII Reactor • Get a tour through all aspects of one of the central sources of Neutrons in Europe to bolster your understanding of the internal requirements of operating such a site • This opportunity is offered to delegates that register for the conference. However, there is a very limited number of spaces available and they will be allocated by a ballot • This was made possible through a collaboration with ITM

<p>Urs Hagemann Laboratory Head Bayer</p>	<p>14.00 Targeted Thorium-227 Conjugates - Exploring the Potential of Bayer's Novel Targeted Alpha Therapy Platform in Solid Tumors</p> <ul style="list-style-type: none"> Learn targeted thorium-227 conjugates (TTCs) represent a new class of molecules for targeted alpha therapy (TAT) The covalent attachment of a 3,2-HOPO chelator to targeting moieties (e.g. tumor antigen targeting antibodies) enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumor cells Due to the high linear energy transfer and short penetration range, TAT efficiently induce double-strand DNA breaks, resulting in apoptosis of tumor cells Preclinical data on various TTCs, including combination potential are being presented
<p>Amal Saidi Scientist OranoMed</p>	<p>14.30 Preclinical Development of ²¹²Pb-DOTAMTATE in a Neuroendocrine Tumor Model</p> <ul style="list-style-type: none"> Although somatostatin analogs have been combined with various beta and gamma emitters over the years, we have developed an octreotate analog in combination with the alpha emitter, ²¹²Pb ²¹²Pb-DOTAMTATE shows tumor targeting of >20% ID/g in mice 24hrs post treatment and was shown to increase median survival > 2-fold with a single dose Kidney protection agents, including lysine and arginine, can minimise drug retention in the kidneys while the addition of ascorbic acid to the drug preparation was found to minimise oxidation of the drug product
<p>Matt Harris Chief Executive Officer Clarity Pharmaceuticals</p> <p>Urs Hagemann Laboratory Head Bayer</p>	<p>15.00 Panel Discussion: Are Targeted Alpha Emitting Therapies the End Game of Radiopharmaceutical Progress?</p> <ul style="list-style-type: none"> What could improve Alpha emitting isotopes further? What new oncological and non-oncological diseases can we target next? Have Beta-emitting therapies reached their maximum potential?
	<p>15.30 Afternoon Refreshments</p>
<p>Ensuring Clinical Success Through Effective Translation, Companion Imaging & Dosimetry</p>	
<p>Maurizio Mariani Head of Research Advanced Accelerator Applications, A Novartis Company</p>	<p>16.00 Relevance of dosimetry and the Lutathera experience</p> <ul style="list-style-type: none"> Target organ dosimetry is a unique asset of Nuclear Medicine. As for the more classical PK/PD approach, dosimetry can be a useful tool to support the identification of potential dose range and therapeutic schemes during development Nevertheless, due to the high variability of data and the intrinsic limitation of the method, dosimetry appears to be of use at the initial stages of development but not suited for a personalized therapeutic approach Experience gained during Lutathera development confirmed that clinical, haematological and biochemical assessments, rather than dosimetry, are the most reliable tools to monitor both efficacy and safety aspects
<p>Marc Robillard Chief Executive Officer Tagworks Pharmaceuticals</p>	<p>16.30 In-Vivo Click Strategies for Antibody-Based Imaging and Radiotherapy</p> <ul style="list-style-type: none"> Learn how pre-targeting using in vivo click chemistry and a secondary radiolabelled probe can boost target-blood ratios in radioimmunoimaging and therapy Learn how click-reactive clearing agents can be used to trigger instantaneous clearance of freely circulating radiolabelled antibodies, boosting target-blood ratios
<p>Twan Lammers Professor, Head of Department Aachen University</p>	<p>17.00 Imaging Biomarkers in Cancer Nanomedicine</p> <ul style="list-style-type: none"> Cancer nanomedicines rely on the EPR effect, which is highly variable Radiolabeling of nanomedicines allows for patient stratification and can be used to individualise and improve antitumor nanotherapy Multiple proof-of-concept studies have recently been published showing the added value of imaging biomarkers on the clinical translation of cancer nanomedicines
	<p>17.30 Chair's Closing Remarks</p>
	<p>17.40 End of Day 1</p>

CONFERENCE DAY TWO

THURSDAY, 13 JUNE

8.50 Chair's Opening Remarks

Enhancing the Clinical Efficacy & Application of Radiopharmaceuticals

Chris Leamon
Vice President of
Research
Endocyte

9.00 Ligand Targeted Cancer Therapy: Shifting from Chemo to Radiotherapy

- Brief development history of small molecule drug conjugates (SMDCs)
- New learning on targeted tubulysin-based agents in the clinic
- Comparison of targeted chemo vs. radioligand therapy
- Overview of ¹⁷⁷Lu-PSMA-617
- Discuss next generation RLT

Jostein Dahle
Chief Scientific
Officer
Nordic Nanovector

9.30 Targeted Alpha Therapy with ²¹²Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

- CD37 is highly and selectively expressed on the surface of mature B lymphocytes and B-cell malignancies and may become a useful alternative to the CD20 target, due to the emergence of resistance to anti-CD20 therapies
- Alpha-emitting radionuclides have demonstrated good potential for cancer targeted therapies because of efficient energy deposition along the short alpha track (50–100 µm) causing irreparable DNA double-strand breaks and localised cytotoxicity while sparing surrounding healthy tissues
- In collaboration with Orano Med, we have developed a targeted alpha therapy (TAT) where the CD37-specific antibody NNV003 is coupled to the alpha-particle generating radioisotope ²¹²Pb and shown that it is a safe and effective method for the treatment of CD37 positive CLL and NHL in preclinical models

Dale Ludwig
Chief Scientific
Officer
**Actinium
Pharmaceuticals**

10.00 Leveraging the Power of Radioimmunotherapy in Cancer Treatment: Radio-Conjugate Therapeutic Combinations and Targeted Conditioning Regimens for Cell Therapy

- Strategic combinations of radiopharmaceuticals and targeted therapies
- Exploiting the potency of alpha and beta emitter radionuclide warheads to effectively condition patients prior to bone marrow transplant and adoptive cell therapies

10.30 Morning Refreshments

Izabella Tworowska
Chief Scientific
Officer
Radiomedix

11.00 Topic to be Confirmed

Melpomeni Fani
Head of
Radiopharmaceutical
Chemistry Research
and Development
**University Hospital
Basel**

11.30 Targeting G-Protein Coupled Receptors with Radiolabelled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside

- Most recent developments in radiolabelled somatostatin analogues: shift from agonists to antagonists
- Peptide-based radiopharmaceuticals beyond somatostatins
- Clinical translation in an academic environment

Greg Mullen Chief Executive Officer Theragnostics	12.00 Novel Targets in Radiopharmaceuticals <ul style="list-style-type: none"> • Look at new targets that are coming through with theranostic, diagnostic and combined capabilities • Discuss important factors to consider when validating novel targets
	12.30 Lunch
Critical Issues in Radiopharmaceutical Production	
Marian Meckel Research & Development Lead ITG	13.30 Manufacturing of EndolucinBeta (Lu-177 Chloride) <ul style="list-style-type: none"> • Nuclide properties • Manufacturing of n.c.a. Lu-177 • Ytterbium lifecycle • Reactor network • Logistics
Chris Behrenbruch Chief Executive Officer Telix Pharmaceuticals	14.00 Current Radiopharmaceutical Manufacturing Challenges: From Pilot to Scale-Up <ul style="list-style-type: none"> • Full details to be disclosed at a later date
	14.30 Afternoon Refreshments
Future Perspectives on Radiopharmaceuticals	
Tony Lahoutte Chief Scientific Officer Camel-IDS	15.00 Single Domain Antibodies in Nuclear Medicine <ul style="list-style-type: none"> • Single domain antibody fragments as a modality • Imaging and therapy; what is the best approach? • Breast cancer as a target indication
Daniel Stevens Global Development Lead IPSEN Diane Chisholm Blue Earth Diagnostics	15.30 Panel Discussion: Clinical Trial Considerations over the Next 12 Months <ul style="list-style-type: none"> • Discuss what changes in legislation could mean for radiopharmaceutical clinical development • Look at current logistical issues with conducting clinical trials and how industry could work to fix them in the next 12 months
	16.00 Chairman's Closing Remarks
	16.10 End of Conference

■ A good meeting in terms of presentation topics, interactive workshop ■
Celgene, Past Hanson Wade Attendee

PRE-CONFERENCE ACTIVITIES

TUESDAY, 11 JUNE

Workshop

Molecular Imaging to Accelerate Oncology Drug Development

12:00 – 15:00

The use of molecular imaging techniques (PET/SPECT/Optical) has tremendous potential to accelerate oncology clinical trials, establish new patient selection strategies and serve as a biomarker of treatment response. In a world beyond RECIST, there is growing interest - and evidence of utility - in the role of imaging. The purpose of this workshop will be to collaboratively explore some of the key opportunities for molecular imaging in oncology drug development, with particular focus on immuno-oncology.

This interactive session will be a combination of presentations and discussions designed to take a deep dive into oncology drug design methodology.

We'll provide the platform to not only learn about new technologies and opportunity, but also give you the chance to analyse the challenges you are facing, in granular detail in an open discussion. By looking at a variety of different cancers, targets and drugs; this comprehensive session is a "can't miss" for any radiopharmaceutical drug developer.

Workshop Leader



Chris Behrenbruch
Chief Executive Officer
Telix Pharmaceuticals

Site Visit

Guided Tour Around the Nuclear Reactor at the Technical University of Munich

15:30-17:00

Join us in a visit to the Munich Technical University's FRMII Reactor. Get a tour through all aspects of one of the central sources of Neutrons in Europe to bolster your understanding of the internal requirements of operating such a site.

This opportunity is offered to delegates that have registered for the conference. However, there is a very limited number of spaces available and they will be allocated by a ballot.

This has been made possible through a collaboration with ITM.

This was made possible through a close collaboration with ITM



FREE


Intimate setting where scientists and clinicians can have focused discussions
Fate Therapeutics, Past Hanson Wade Attendee

SPONSOR

WHY SPONSOR?

Targeted Radiopharmaceuticals Summit is a unique opportunity to engage directly with the organisations, industry and academic, who will lead this growing field this year. If you have capabilities that would benefit our audience in the theranostic and/or diagnostic space, this meeting provides a unique platform to showcase your solutions, generate new business leads and source opportunities for partnerships. Act now to stay ahead of the curve and seize the wealth of opportunity on offer. Get in touch today for more information about the various partnership opportunities available.

EXPECTED ATTENDEE SENIORITY*



C-Level & VP: 20%

Director & Above: 35%

Scientist & Team
Leader: 30%

Academic: 15%

Excellent meeting. Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities

Merck, Past Hanson Wade Attendee

This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics

AstraZeneca, Past Hanson Wade Attendee

*Based on typical Hanson Wade events

CURRENT ATTENDEES INCLUDE



Actinium Pharmaceuticals, Inc.



THERAGNOSTICS

GET INVOLVED



Nathan Wilgoss

Partnership Director

Tel: +44 20 3587 7765

Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK



www.targeted-radiopharma.com/register



Tel: +44 20 3141 8700



Email: register@hansonwade.com

- 1 Join the peer-led discussion into the critical issues behind the technical advancement of the next generation of radiopharmaceuticals
- 2 Gain key insights that will inform your steps forward through preclinical testing, translation and clinical trials
- 3 Hear how industry leaders are approaching the important logistical issues behind planning and executing radiopharmaceutical trials

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5+ delegates

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.
Contact: register@hansonwade.com

SECURE YOUR PLACE

Standard Pricing	Register & Pay by Friday 15 March	Standard Prices
Conference + 1 Workshop	€2,898 (save €400)	€3,198 (save €100)
Conference Only	€2,399 (save €300)	€2,699
Workshop Only	€599	
Site Visit	FREE	

Start-up & Academic*	Register & Pay by Friday 15 March	Standard Prices
Conference + 1 Workshop	€1,598 (save €400)	€1,898 (save €100)
Conference Only	€1,299 (save €300)	€1,599
Workshop Only	€399	
Site Visit	FREE	

*T&Cs Apply: Start-up rate is subject to organiser approval. Please visit the event website for more details.

*VAT will be charged at 19%.



VENUE

Marriott Munich Hotel

Berliner Str. 93, 80805 München, Germany

For further information or assistance, please visit
www.marriott.com/hotels/travel/mucno-munich-marriott-hotel/

TERMS & CONDITIONS

*Team discounts only apply when booking a full 2-day conference package, and cannot be used in conjunction with any other discount (including academic or start-up rates). Group discounts can still be applied to earlybird savings. For more information on group rates and eligibility criteria, please email info@hansonwade.com or visit the website. Full T&Cs apply. Full payment is due on registration.

Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future

conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God,

natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH